Search Results - "Svedman, F Costa"

Surgical outcomes in patients with cutaneous malignant melanoma in Europe – a systematic literature review by Costa Svedman, F., Spanopoulos, D., Taylor, A., Amelio, J., Hansson, J.

“…There is limited comparative evidence of the outcomes of different types of surgical management in patients with malignant melanoma in Europe. To address that…”
Get full text

Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy—a retrospective and biomarker study by Costa Svedman, F., Liapi, M., Månsson-Broberg, A., Chatzidionysiou, K., Egyhazi Brage, S.

“…Immune-related adverse events (IRAEs) during therapy with immune checkpoint inhibitors (ICIs) are common, and their management sometimes requires…”
Get full text

Toxicity and one-year tumor control with induction chemotherapy and bioradiotherapy for locally advanced unresectable head and neck cancer by Mercke, C., Haugen, H., Adell, G., Costa-Svedman, F., Nyman, J., Wickart-Johansson, G., Sjödin, H.

“…Abstract only…”
Get full text

866P Inflammation proteins associated with worse clinical outcome to treatment with anti-PD1 in metastatic cutaneous melanoma by Costa Svedman, F., Helgadottir, H., Egyhazi Brage, S.

Get full text

1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI) by Costa Svedman, F., Liapi, M., Chatzidionysiou, A., Månsson-Broberg, A., Egyhazi Brage, S.

Get full text

2383P Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience by Jawdat, F., Costa Svedman, F., Holmsten, K., Grozman, V., Alm, D., Hailom, W.S., Ullén, A.

Get full text

1369P - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma by Svedman, F Costa, Das, I., Tuominen, R., Ramqvist, E.D., Hansson, J., Höiom, V., Brage, S Egyhazi

“…Immune checkpoint inhibitors (ICI) have improved clinical outcome for many patients with advanced cutaneous malignant melanoma (CMM) during the last decade…”
Get full text

1369PGenes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma by Svedman, F Costa, Das, I, Tuominen, R, Ramqvist, E D, Hansson, J, Höiom, V, Brage, S Egyhazi

“…Abstract Background Immune checkpoint inhibitors (ICI) have improved clinical outcome for many patients with advanced cutaneous malignant melanoma (CMM) during…”
Get full text

Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI) by Svedman, F. Costa, Yang, M., Tuominen, R., Brage, S.E., Höiom, V.

Get full text

LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 by Fernandez, A.M. Arance, O'Day, S.J., Merino, L. de la Cruz, Petrella, T., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Márquez-Rodas, I., Spreafico, A., Victoria Atkinson, V., Costa Svedman, F., Smith, A.D., Chen, K., Diede, S.J., Krepler, C., Long, G.V.

Get full text

Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma by Svedman, F Costa, Das, I., Tuominen, R., Ramqvist, E.D., Hansson, J., Höiom, V., Brage, S Egyhazi

Get full text

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era by Holmsten, Karin, Eknert, Johanna, Öfverholm, Elisabeth, Papantoniou, Dimitrios, Jawdat, Faith, Verbiéné, Ingrida, Laurell, Anna, Jänes, Elin, Sandzén, Johan, Wojtyna-Dziedzic, Elzbieta, Lagstam, Ida, Söderkvist, Karin, Costa Svedman, Fernanda, Liedberg, Fredrik, Bruzelius, Martin, Fransson, Ann-Sofie, Kjellström, Sofia, Omland, Lise Hoej, Pappot, Helle, Ullén, Anders

“…Immune checkpoint inhibitors (ICIs) have been established as a routine treatment in patients with metastatic urothelial cancer (mUC). However, there has been…”
Get full text

217P Characterization of immune cells in the tumor microenvironment of advanced bladder cancer by Flaberg, E., Turkki, R., Paavolainen, L., Krantz, D., Välimäki, K., Schoonenberg, A., Moussaud, E., Holmsten, K., Costa Svedman, F., Kallioniemi, O., Abrahamsson, J., Liedberg, F., Sjödahl, G., Pellinen, T., Ullén, A., Östling, P.

Get full text

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors by Costa Svedman, Fernanda, Jalsenius, Marie, Höiom, Veronica, Grozman, Vitali, Bergqvist, Mattias, Söderdahl, Fabian, Eriksson, Hanna, Rotstein, Samuel, Ny, Lars, Ascierto, Paolo A, Brage, Suzanne Egyhazi, Helgadottir, Hildur

“…Immune checkpoint inhibitors (ICI) are effective in fractions of patients with disseminated melanoma. This study is the first to analyze the plasma activity of…”
Get full text

Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma (CMM) by Eriksson, Hanna, Lohcharoenkal, Warangkana, Costa-Svedman, Fernanda, Sonkoly, Eniko, Brage, Suzanne Egyhazi, Hansson, Johan, Pivarcsi, Andor

“…Abstract only…”
Get full text

Overview of immune-related side effects from immune checkpoint inhibitors. Part 1: Gastrointestinal, lung and kidney toxicity by Villabona Lisa Villabona, Lisa, Costa Svedman, Fernanda, Jovanovic, Braslav, Kaneteg, Birgitta, Eberhardson, Michael, Magin, Hasan, Ullenhag, Gustav, Blomqvist, Lennart, Helgadottir, Hildur

“…In the past decade, immunotherapy with checkpoint inhibitors has revolutionized the field of oncology. Checkpoint inhibitors have been approved for several…”
Get more information

The ACCROBAT I study: Three-year follow-up of a prospective phase II study with neoadjuvant TPF before bioradiotherapy for stage III-IV unresectable squamous cell head and neck cancer by Mercke, Clas, Sjödin, Helena, Haugen, Hedda, Wickart-Johansson, Gun, Costa-Svedman, Fernanda, von Dobeln, Gabriella, Margolin, Gregori, Hellstrom, Mats, Nyman, Jan

“…Abstract only…”
Get full text